Cystic Fibrosis Failure Weakens PTC's Duchenne Argument, FDA Says

US FDA sees parallels in ataluren’s development in Duchenne and firm's unsuccessful efforts to find efficacious subsets in cystic fibrosis.

Two sets of railroad tracks run straight and parallel to a vanishing point on the horizon with green trees along side.

More from US FDA Performance Tracker

More from Regulatory Trackers